Jump to navigation Jump to search
Clinical data
Routes of
Oral, Subcutaneous, Intravenous
ATC code
CAS Number
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Sulodexide


Most recent articles on Sulodexide

Most cited articles on Sulodexide

Review articles on Sulodexide

Articles on Sulodexide in N Eng J Med, Lancet, BMJ


Powerpoint slides on Sulodexide

Images of Sulodexide

Photos of Sulodexide

Podcasts & MP3s on Sulodexide

Videos on Sulodexide

Evidence Based Medicine

Cochrane Collaboration on Sulodexide

Bandolier on Sulodexide

TRIP on Sulodexide

Clinical Trials

Ongoing Trials on Sulodexide at Clinical

Trial results on Sulodexide

Clinical Trials on Sulodexide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Sulodexide

NICE Guidance on Sulodexide


FDA on Sulodexide

CDC on Sulodexide


Books on Sulodexide


Sulodexide in the news

Be alerted to news on Sulodexide

News trends on Sulodexide


Blogs on Sulodexide


Definitions of Sulodexide

Patient Resources / Community

Patient resources on Sulodexide

Discussion groups on Sulodexide

Patient Handouts on Sulodexide

Directions to Hospitals Treating Sulodexide

Risk calculators and risk factors for Sulodexide

Healthcare Provider Resources

Symptoms of Sulodexide

Causes & Risk Factors for Sulodexide

Diagnostic studies for Sulodexide

Treatment of Sulodexide

Continuing Medical Education (CME)

CME Programs on Sulodexide


Sulodexide en Espanol

Sulodexide en Francais


Sulodexide in the Marketplace

Patents on Sulodexide

Experimental / Informatics

List of terms related to Sulodexide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Sulodexide is a highly purified mixture of glycosaminoglycans composed of low molecular weight heparin (80%) and dermatan sulfate (20%).


The low molecular weight of both sulodexide fractions allows for extensive oral absorption compared to unfractionated heparin. The pharmacological effects of sulodexide differ substantially from other glycosaminoglycans and are mainly characterized by a prolonged half-life and reduced effect on global coagulation and bleeding parameters.[1] Due to the presence of both glycosaminoglycan fractions, sulodexide potentiates the antiprotease activities of both antithrombin III and heparin cofactor II simultaneously.[2]


Clinically, sulodexide is used for the prophylaxis and treatment of thromboembolic diseases however recent research has also demonstrated the beneficial effects of sulodexide in animal models of reperfusion injury[3] and the treatment of diabetic nephropathy.[4][5][6] In combination with Melatonin, Sulodexide have been shown to be a viable treatment option for patients suffering from central or sensorineural tinnitus.[7][8]


  1. Lauver DA, Lucchesi BR (2006). "Sulodexide: a renewed interest in this glycosaminoglycan". Cardio drug rev. 24 (3–4): 214–26. doi:10.1111/j.1527-3466.2006.00214.x. PMID 17214598.
  2. Harenberg J (1998). "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide". Med Res Rev. 18 (1): 1–20. doi:10.1002/(SICI)1098-1128(199801)18:1<1::AID-MED1>3.0.CO;2-4. PMID 9436179.
  3. Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR (2005). "Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis". J Pharmacol Exp Ther. 312 (2): 794–800. doi:10.1124/jpet.104.075283. PMID 15365091.
  4. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. (2005). "One year course of oral sulodexide in the management of diabetic nephropathy". J Nephrol. 18 (5): 568–574. PMID 16299683.
  5. Gambaro G, Venturini AP, Noonan DM; et al. (1994). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Kidney Int. 46 (3): 797–806. doi:10.1038/ki.1994.335. PMID 7527876.
  6. Škrhaa J, , J Perušičováb J; et al. (1997). "Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy". Diabetes Res Clin Practice. 38 (1): 25–31. doi:10.1016/S0168-8227(97)00076-4. PMID 9347243.
  7. Neri G, Baffa C, De Stefano A; et al. (2009). "Management of tinnitus: oral treatment with melatonin and sulodexide". J. Biol. Regul. Homeost. Agents. 23 (2): 103–10. PMID 19589291.
  8. Neri G. De Stefano A. Baffa C. Kulamarva G. Di Giovanni P. Petrucci G. Poliandri A. Dispenza F. Citraro L. Croce A. ,"Treatment of central and sensorineural tinnitus with orally administered Melatonin and Sulodexide: personal experience from a randomized controlled study." Acta Otorhinolaryngologica Italica. 29(2):86-91, 2009 Apr.